Intravenous L-carnitine and acetyl-L-carnitine in medium-chain acyl-coenzyme A dehydrogenase deficiency and isovaleric acidemia.
The purpose of this study was to determine whether treatment with L-carnitine or acetyl-L-carnitine enhances the turnover of lipid or branched-chain amino acid oxidation in patients with inborn errors of metabolism. Increasing i.v. doses of L-carnitine and acetyl-L-carnitine were given to one patient with medium-chain acyl-CoA dehydrogenase deficiency and to another with isovaleric acidemia. Both patients were in stable condition and receiving oral L-carnitine supplements. The excretion of carnitine and disease-specific metabolites was measured. The incorporation of L-carnitine in the intracellular pool was demonstrated using stable isotopes and mass spectrometry. Increasing doses of either i.v. L-carnitine or acetyl-L-carnitine did not stimulate the excretion of octanoylcarnitine in the patient with medium-chain acyl-CoA dehydrogenase deficiency, nor did it raise the plasma levels of either cis-4-decenoate or octanoylcarnitine. Similarly, increasing doses of either i.v. L-carnitine or acetyl-L-carnitine did not enhance the excretion of isovalerylcarnitine in a patient with isovaleric acidemia. The excretion of isovalerylglycine actually decreased. We conclude that there was no evidence of enhanced fatty acid beta-oxidation or enhanced branched-chain amino acid oxidation in vivo by the administration of high doses of L-carnitine or acetyl-L-carnitine in these two patients. Because only one individual with each disorder was studied, the data are only indicative and may not necessarily be representative of all individuals with these disorders. Definite settlement of this issue will require further studies in additional subjects.
Van Hove
J L
JL
Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710.
Kahler
S G
SG
Millington
D S
DS
Roe
D S
DS
Chace
D H
DH
Heales
S J
SJ
Roe
C R
CR
D000108:Acetylcarnitine / Q000008:administration & dosage* / Q000493:pharmacokinetics; D042964:Acyl-CoA Dehydrogenase; D044944:Acyl-CoA Dehydrogenases / Q000172:deficiency*; D000592:Amino Acid Metabolism, Inborn Errors / Q000188:drug therapy / Q000378:metabolism; D002331:Carnitine / Q000008:administration & dosage* / Q000493:pharmacokinetics; D002675:Child, Preschool; D005260:Female; D045782:Hemiterpenes; D006801:Humans; D007275:Injections, Intravenous; D008052:Lipid Metabolism, Inborn Errors / Q000188:drug therapy / Q000378:metabolism; D010421:Pentanoic Acids / Q000097:blood*; D012449:Safety
D045782:Hemiterpenes; D010421:Pentanoic Acids; C008216:isovaleric acid; D000108:Acetylcarnitine; D044944:Acyl-CoA Dehydrogenases; D042964:Acyl-CoA Dehydrogenase; D002331:Carnitine